BLRX Projected Dividend Yield
ADR (Sponsored) (New)/BioLineRx Ltd ( NASDAQ : BLRX )BioLineRx is a late clinical-stage biopharmaceutical development company with a focus on oncology. Co.'s development and commercialization pipeline consists of two clinical-stage therapeutic candidates: motixafortide (BL-8040), a peptide for the treatment of stem cell mobilization, solid tumors and acute myeloid leukemia, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, Co. has a therapeutic product called BL-5010 for the treatment of skin lesions. 21 YEAR PERFORMANCE RESULTS |
BLRX Dividend History Detail BLRX Dividend News BLRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |